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Abstract. 
 
The syntrophins are a multigene family of in-
tracellular dystrophin-associated proteins comprising 
three isoforms, 
 
a
 
1, 
 
b
 
1, and 
 
b
 
2. Based on their domain 
organization and association with neuronal nitric oxide 
synthase, syntrophins are thought to function as modu-
lar adapters that recruit signaling proteins to the mem-
brane via association with the dystrophin complex. Us-
ing sequences derived from a new mouse 
 
b
 
1-syntrophin 
cDNA, and previously isolated cDNAs for 
 
a
 
1- and 
 
b
 
2-
syntrophins, we prepared isoform-specific antibodies to 
study the expression, skeletal muscle localization, and 
dystrophin family association of all three syntrophins. 
Most tissues express multiple syntrophin isoforms. In 
mouse gastrocnemius skeletal muscle, 
 
a
 
1- and 
 
b
 
1-syn-
trophin are concentrated at the neuromuscular junction 
but are also present on the extrasynaptic sarcolemma. 
 
b
 
1-syntrophin is restricted to fast-twitch muscle fibers, 
the first fibers to degenerate in Duchenne muscular 
dystrophy. 
 
b
 
2-syntrophin is largely restricted to the 
neuromuscular junction.
The sarcolemmal distribution of 
 
a
 
1- and 
 
b
 
1-syntro-
phins suggests association with dystrophin and dystro-
brevin, whereas all three syntrophins could potentially 
associate with utrophin at the neuromuscular junction. 
Utrophin complexes immunoisolated from skeletal 
muscle are highly enriched in 
 
b
 
1- and 
 
b
 
2-syntrophins, 
while dystrophin complexes contain mostly 
 
a
 
1- and 
 
b
 
1-
syntrophins. Dystrobrevin complexes contain dystro-
phin and 
 
a
 
1- and 
 
b
 
1-syntrophins. From these results, 
we propose a model in which a dystrophin–dystrobre-
vin complex is associated with two syntrophins. Since 
individual syntrophins do not have intrinsic binding 
specificity for dystrophin, dystrobrevin, or utrophin, the 
observed preferential pairing of syntrophins must de-
pend on extrinsic regulatory mechanisms.
 
S
 
yntrophins 
 
are intracellular peripheral membrane
proteins of 58–60 kD originally identified as pro-
teins enriched at the postsynaptic apparatus in 
 
Tor-
pedo
 
 electric organ (17). More recently, syntrophins in
mammalian skeletal muscle have been shown to be part of
a complex of proteins that associate with dystrophin, the
product of the Duchenne/Becker muscular dystrophy gene
(4, 28, 50, 54). Many of the dystrophin-associated proteins
(DAPs)
 
1
 
 are transmembrane proteins. Thus, the dystrophin
complex as a whole is thought to link cortical actin to the
extracellular matrix, thereby stabilizing the sarcolemma
during repeated cycles of contraction and relaxation (3).
At the neuromuscular junction (NMJ), the DAPs have been
implicated in agrin-stimulated clustering of nicotinic ace-
tylcholine receptors (for review see reference 46). Dystro-
phin and DAPs are also found at synapses in the brain and
retina (29, 33, 45). Thus, the syntrophins and other DAPs
may participate in synaptogenesis as well as in sarcolem-
mal stabilization.
The three syntrophin isoforms, 
 
a
 
1, 
 
b
 
1, and 
 
b
 
2, are en-
coded by different genes but have similar domain organi-
zations. All known syntrophins contain two pleckstrin ho-
mology (PH) domains (2, 19), which are modules of 
 
z
 
100
amino acids found in a wide array of signaling proteins.
PH domains in other proteins bind phosphatidylinositol
lipids and proteins, such as the 
 
bg
 
-subunits of trimeric G
proteins (for review see reference 47). Thus, PH domains
may mediate signal-dependent membrane association. In-
serted within the first syntrophin PH domain is a PDZ do-
main (originally identified in postsynaptic density-95, discs
large, ZO-1), a 90–amino acid domain found in more than
40 proteins, many of which are restricted to membrane
specializations such as tight junctions or synapses (48). A
trend emerging from study of other PDZ-containing pro-
teins suggests that PDZ domains bind the cytoplasmic car-
boxy-terminal tails of transmembrane proteins (examples
 
of which include NMDA receptors, K
 
1
 
 channels, Fas [42],
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1. 
 
Abbreviations used in this paper
 
: DAPs, dystrophin-associated proteins;
DMD, Duchenne muscular dystrophy; DRP, dystrophin-related protein;
HB, homogenization buffer; MAGUK, membrane-associated guanylate
kinase; MHC, myosin heavy chain; NMJ, neuromuscular junction; nNOS,
neuronal nitric oxide synthase; PDZ, protein domain originally identified
in postsynaptic density-95, discs large, ZO-1; PH, pleckstrin homology;
SU, syntrophin-unique.
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and EGF receptors (for review see reference 48]). Finally,
the COOH-terminal 57 amino acids of syntrophins are
highly conserved among the three isoforms but are other-
wise unique. This region, termed the syntrophin-unique
(SU) domain, may contain the binding site for dystrophin
family members (2, 6). Thus, the syntrophins are a family
of multidomain proteins that likely function as modular
adapters in recruiting signaling proteins to dystrophin
complexes and the membrane.
Differential association of dystrophin with certain syn-
trophin isoforms and/or DAPs may play a role in tailoring
the complex for a particular membrane specialization. In-
deed, the protein complexes assembled by muscle dystro-
phin should be functionally distinct from those organized
by retinal dystrophin. Likewise, each of the dystrophin-
related proteins, utrophin, dystrophin-related protein 2
(DRP-2), and dystrobrevin, may differentially associate
with particular DAPs in different cell types. All of these
dystrophin family members contain amino acid sequences
homologous to the dystrophin carboxy terminus, the re-
gion in dystrophin shown to bind syntrophins and the
DAPs. Dystrophin, utrophin, and dystrobrevin have been
shown to be capable of binding all three syntrophin iso-
forms in vitro (4, 6). With the exception of dystrobrevin,
each dystrophin family member also has a WW domain
postulated to bind the transmembrane DAP complex.
Since each of the dystrophin family members is expressed
in a wide range of cell types, their association with specific
subsets of syntrophins/DAPs may be critical for cell-spe-
cific function.
Among all the DAPs, the syntrophins appear particu-
larly well suited for differentially associating with the dys-
trophin family members. Each of the three syntrophins
is postulated to function as a modular adapter recruiting
signaling proteins to dystrophin membrane complexes.
Yet, syntrophin isoforms share only 
 
z
 
50% amino acid
identity, suggesting that each may recruit a distinct set of
proteins. Like members of the dystrophin family, the syn-
trophins are expressed in a wide range of tissues (1, 5).
We have shown previously that in rat skeletal muscle, 
 
a
 
1-
syntrophin is localized on the sarcolemma with dystrophin,
whereas 
 
b
 
2-syntrophin is restricted to the NMJ, similar to
utrophin (38). In contrast, the transmembrane dystrogly-
cans are expressed in many tissues and are the products of
a single gene (for review see reference 21). The sar-
coglycans are comprised of multiple forms, but these are
highly restricted to muscle (35, 53). In addition, most sar-
coglycans are unrelated in amino acid sequence (32, 35),
suggesting that they have distinct functions. Thus, among
the known DAPs, syntrophins are leading candidates for
associating with different dystrophin family members and
could be involved in targeting of dystrophin family mem-
bers to distinct membrane sites, or in conferring different
functions to DAP complexes.
Here, we examine the associations of all three syntro-
phin isoforms with dystrophin family members expressed
in skeletal muscle. We have previously isolated mouse
cDNAs encoding 
 
a
 
1- and 
 
b
 
2-syntrophins (1) and exam-
ined the corresponding protein localization (38). However,
these studies did not consider the recently described mam-
malian dystrobrevins (8, 41) or 
 
b
 
1-syntrophin (5). We be-
gan this study by isolating the mouse 
 
b
 
1-syntrophin cDNA
and generating and characterizing isoform-specific anti-
bodies. These isoform-specific antibodies were then used
to define the distribution of each syntrophin and the asso-
ciation of syntrophins with dystrophin, utrophin, and dys-
trobrevin isoforms from normal, dystrophin-deficient, and
 
D
 
71–74 dystrophin transgenic mouse skeletal muscle. We
find that pairs of syntrophin isoforms selectively copurify
with dystrophin and utrophin. Based on these results, we
propose a model in which particular pairs of syntrophin
isoforms associate with dystrophin/dystrobrevin or utro-
phin/dystrobrevin complexes.
 
Materials and Methods
 
Mouse 
 
b
 
1-Syntrophin cDNA Isolation
 
A 
 
l
 
gt11 mouse liver cDNA library (Clontech Labs, Palo Alto, CA) was
screened by hybridization with 
 
32
 
P-labeled human 
 
b
 
1-syntrophin cDNA
(a generous gift of Dr. Louis Kunkel, Howard Hughes Medical Institute,
Boston, MA) by methods described previously (1). Five clones were iso-
lated, but none of them contained the extreme 5
 
9
 
 coding region. There-
fore, this sequence was obtained by two consecutive rounds of 5
 
9
 
 rapid
amplification of cDNA ends using a kit purchased from GIBCO BRL
(Gaithersburg, MD) and RNA isolated from C57Bl6 mouse liver (13). PCR
products were amplified with Vent polymerase (NEB) using the sequence-
specific primers 5
 
9
 
-CCTAATCTTGGAGACTCAGGTGG (round 1) and
5
 
9
 
-TCCCGCAGGTCTGCTCCGTTC (round 2). Resulting DNA from
each round was cloned into Bluescript II (Stratagene, La Jolla, CA), and
multiple clones were sequenced by the University of North Carolina Au-
tomated DNA Sequencing Facility (Chapel Hill, NC) on a DNA se-
quencer (model 373A; Applied Biosystems, Inc., Foster City, CA). Se-
quence was analyzed with the aid of a DNAStar Lasergene computer
software package (Madison, WI).
 
Antibodies
 
Antisyntrophin.  
 
mAb SYN1351 raised against 
 
Torpedo
 
 syntrophin has
been described previously (17). Polyclonal antibodies (Abs) specific for
each syntrophin isoform were prepared by immunizing rabbits with pep-
tides according to standard methods (36). The Ab SYN37 was prepared
against the peptide C-RLGGGSAEPLSSQSFSFHRDR, corresponding to
amino acids 220–240 of mouse 
 
b
 
1-syntrophin, plus an NH
 
2
 
-terminal cys-
teine (see boxed region in Fig. 1 
 
B
 
). The 
 
b
 
2-syntrophin antibody, SYN28,
was prepared against C-SGSEDSGSPKHQNTTKDR as an alternative to
the weaker Ab SYN24 previously prepared against the same peptide (38).
The 
 
a
 
1-syntrophin antibody, SYN17, was described previously (38). Each
antipeptide antibody used in this study was affinity purified with peptide
coupled to Affi-Gel-10 or -15 (BioRad Labs, Hercules, CA) as described
previously (28) and was used directly or after biotinylation with sulfo-NHS-
biotin (Pierce, Rockford, IL) according to the manufacturer’s protocol.
 
Antidystrobrevin.  
 
mAb 13H1 (a gift of J.B. Cohen, Harvard Medical
School) was raised against 
 
Torpedo
 
 dystrobrevin (12). Abs DB308 and
DB433 were prepared against peptides corresponding to mouse dystro-
brevin, as previously described (8).
 
Antidystrophin.  
 
Ab DYS3669 was prepared against COOH-terminal
10 amino acids of mouse dystrophin (22) plus a terminal cysteine (C-PGK-
PMREDTM) according to standard methods (36). mAb Mandys-8 (34)
was purchased from Sigma Chemical Co. (St. Louis, MO).
 
Antiutrophin.  
 
Ab UTR3165 was previously described (28). mAb DRP-1
was purchased from Novacastra Laboratories (Newcastle upon Tyne, UK).
 
Anti–myosin heavy chain (MHC).  
 
mAbs BF-F3 (diluted 1:30) (44) and
NCL-MHCf (Novacastra Laboratories, diluted 1:30) are specific for MHC
expressed in type IIB fibers and all type II fibers, respectively. mAb A4.74
(diluted 1:30) (52) strongly labels rat MHC in type IIA and labels type IID
fibers to a lesser extent.
 
Immunoaffinity Purification of Protein Complexes
 
Tissues from control (C57BL10 SNJ; Jackson Laboratory, Bar Harbor,
ME), 
 
mdx
 
 (Jackson Laboratory), and 
 
D
 
71–74/
 
mdx
 
 mice (J.S. Chamber-
lain, University of Michigan, Ann Arbor, MI) (39) were dissected and fro-
zen in liquid nitrogen. Protein complexes were partially purified as de- 
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scribed previously (28). Briefly, tissues (5 g) were homogenized in 10 vol
(wt/vol) of ice-cold homogenization buffer (HB; 10 mM Na phosphate, 0.4 M
NaCl, 5 mM EDTA, pH 7.8, plus the protease inhibitors aprotinin, leupep-
tin, and antipain at 0.5 
 
m
 
g/ml each, pepstatin A, 0.05 
 
m
 
g/ml, and 2 mM
PMSF) (28). The particulate fraction was pelleted (10 min at 12,000 
 
g
 
,
model JA-20 rotor; Beckman Instruments, Fullerton, CA), resuspended in
HB (10 vol), and recentrifuged. Washed pellets were solubilized in 1%
Triton X-100/HB (3 vol) and incubated on ice for 15 min. For preparation
of individual syntrophin isoforms (see Fig. 2), the particulate fractions
were dissolved in 1% SDS/HB (3 vol) to disrupt possible complexes of
multiple syntrophins. After incubation for 15 min, excess 1% Triton/HB
(30 vol) was added. In all cases, the detergent-solubilized extracts were
clarified by centrifugation (20 min at 53,000 
 
g
 
, model Ti 60 rotor; Beck-
man Instruments, Fullerton, CA) and incubated with antibody resins pre-
pared by coupling 2 mg of affinity-purified antibody to 2 ml of Affi-gel 10
(BioRad Labs) according to manufacturer’s specifications. After agitation
for 2 h at 4
 
8
 
C, resins were collected in a column and washed sequentially
with 1% Triton/HB (50 ml), 0.1% Triton/HB (10 ml), and HB (5 ml).
Bound proteins were eluted with 0.1 M triethylamine, pH 11.5, precipi-
tated with TCA, washed with 95% ethanol, and resuspended in SDS-
PAGE sample buffer.
 
Immunoblotting
 
Samples were resolved by electrophoresis on 8% acrylamide/0.8% bis-
acrylamide gels buffered with tris-tricine (43). Proteins were transferred
to Immobilon-P (Millipore Corp., Bedford, MA) in 192 mM glycine, 25 mM
Tris, 20% methanol using a Trans-Blot apparatus (BioRad Labs). After
blocking in 5% milk/TBS, 0.1% tween-20 (TBST), membranes were incu-
bated with primary antibodies (30 nM) in 1% milk/TBST. After three
5-min washes in TBST, bound primary antibodies were detected with ap-
propriate secondary antibodies conjugated to horseradish peroxidase (Jack-
son Immunoresearch, West Grove, PA). Because the heavy chain of poly-
clonal antibodies that leaked from resins comigrated with syntrophins,
selected blots were probed with biotinylated antisyntrophin polyclonal an-
tibodies and detected with peroxidase-avidin detection reagent (Vectastain
ABC elite; Vector Laboratories, Burlingame, CA). Bands were visualized
by enhanced chemiluminescence (Pierce) and exposed to film (Dupont/
NEN, Wilmington, DE). In some cases, blots were stripped for 1 h at 50
 
8
 
C in
2% SDS, 0.1 M 
 
b
 
-mercaptoethanol, 62.5 mM Tris, pH 6.7, and reprobed as
above. Prestained standards (Sigma Chemical Co.) were used after cali-
bration with unstained molecular weight markers (BioRad Labs).
 
Immunohistochemistry
 
The gastrocnemius, plantaris, and soleus were removed intact from mice,
flash-frozen in liquid nitrogen–cooled isopentane, and cryosectioned (7 
 
m
 
m).
Before labeling, sections were fixed with 0.5% paraformaldehyde, perme-
abilized with 0.5% Triton X-100/PBS/0.2 M NH
 
4
 
Cl, and blocked with PBS
containing 2% fish gelatin/0.08% BSA. Sections were incubated with pri-
mary antibodies (30 nM). After several PBS washes, sections were incu-
bated with a cocktail containing either goat anti–rabbit IgG or anti–mouse
IgM conjugated to Texas red (Jackson Immunoresearch; 1:200) mixed
with either donkey anti–mouse IgG conjugated FITC or 
 
a
 
-bungarotoxin (Tx)
conjugated to BODIPY-fluorescence (Molecular Probes, Eugene, OR;
1:300). Washed sections were fixed with 4% paraformaldehyde and
mounted in glycerol containing 
 
n
 
-propyl gallate to reduce photobleaching
(20). Antibody specificity was tested by preincubating antibodies with
their antigenic peptide (100 
 
m
 
M) for 30 min before labeling. Adjacent
sections were stained with Mayers haematoxylin-eosin (30). Sections
were viewed on a fluorescence microscope (model Axioskop; Carl Zeiss,
Inc., Thornwood, NY) and photographed (TMax 400 film; Kodak, Roch-
ester, NY).
 
Results
 
Isolation of Mouse 
 
b
 
1-syntrophin cDNA
 
The cDNA encoding the mouse form of 
 
b
 
1-syntrophin was
obtained by screening a mouse 
 
l
 
gt11 cDNA library with the
human 
 
b
 
1-syntrophin cDNA. Five clones were isolated
containing overlapping sequence that included 
 
.
 
70% of
the protein coding sequence and 820 base pairs of 3
 
9
 
 un-
translated region. The remaining 5
 
9
 
 coding sequence was
obtained by rapid amplification of cDNA ends (see Mate-
rials and Methods). The resulting cDNA (Fig. 1 
 
A
 
) con-
tains 354 nucleotides 5
 
9
 
 of a 1,611-nucleotide open reading
frame. The first methionine codon is in a context favoring
translation initiation (27) and aligns with that described
for the human cDNA (5). The deduced protein contains
537 amino acids and has a predicted mass of 58,088 D and
a pI of 8.3. Its amino acid sequence is 90% identical to hu-
man 
 
b
 
1-syntrophin while sharing only 48 and 55% identity
with human 
 
a
 
1- and 
 
b
 
2-syntrophins, respectively, indicat-
ing that it is the mouse ortholog of human 
 
b
 
1-syntrophin
(5). After the initial methionine, the amino termini of both
Figure 1. Cloning, sequence, and domain structure of murine
b1-syntrophin sequence. (A) Strategy for cloning mouse b1-syn-
trophin and structure of the combined cDNAs, showing the cod-
ing region bounded by start and stop codons. (B) The deduced
amino acid sequence of mouse b1-syntrophin is aligned with
mouse a1- and b2-syntrophins (1, 2). Identical amino acids are
shaded. The boundaries of PH (6, 19), PDZ (2), and SU (2) do-
mains are indicated by arrows. The boxed region denotes se-
quences used to generate synthetic peptides for production of iso-
form-specific antibodies. (C) Schematic diagram showing the
relative organization of PH, PDZ, and SU domains in syntrophins.
Mouse b1-syntrophin cDNA sequence data are available from
GenBank/EMBL/DBJ under the accession number U89997. 
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mouse and human 
 
b
 
1-syntrophin have a stretch of nine
hydrophobic amino acids (alanine and valine). A similar
sequence is present in the human 
 
b
 
2-syntrophin (6) se-
quence but is absent in mouse 
 
b
 
2-syntrophin (2) and the
 
a
 
1-syntrophins (1, 6, 54). Comparison of the amino acid
sequences of the three mouse syntrophins shows marked
conservation, particularly within the PDZ and SU do-
mains (Fig. 1 
 
B
 
).
 
Specificity of Syntrophin Antibodies
 
To investigate the expression of syntrophins and their as-
sociation with dystrophin and dystrophin-related proteins,
we prepared and characterized a series of antisyntrophin
antibodies. Polyclonal antibodies were generated against
synthetic peptides corresponding to syntrophin sequences
from a region poorly conserved among the three isoforms
(see boxed region in Fig. 1 
 
B
 
). To test the specificity of these
antibodies, syntrophin isoforms were partially purified with
the appropriate syntrophin peptide antibody from mouse
tissues rich in either 
 
a
 
1-, 
 
b
 
1-, or 
 
b
 
2-syntrophin (skeletal
muscle, liver, and kidney, respectively). To ensure that each
preparation contained only a single syntrophin, samples
were first treated with SDS to disrupt possible multimeric
complexes and were then diluted with Triton X-100 before
immunopurification. As expected from previous results
(38), immunoblotting with the anti–
 
a
 
1-syntrophin anti-
body, SYN17, labeled a single 
 
z
 
60-kD protein in the 
 
a
 
1-
syntrophin preparation but did not recognize proteins in
either the 
 
b
 
1- or 
 
b2-syntrophin preparations (Fig. 2). Like-
wise, the anti–b1-syntrophin antibody, SYN37, strongly la-
beled proteins in the b1-syntrophin preparation without
recognizing proteins in either the a1- or b2-syntrophin
preparations. Finally, the b2-syntrophin antibodies, SYN24
and SYN28, recognized only b2-syntrophin. In contrast,
mAb SYN1351, which recognizes an epitope in the PDZ
domain (M.E. Adams, S.H. Gee, and S.C. Froehner, un-
published results), strongly labeled each syntrophin iso-
form (Fig. 2). Thus, we conclude that mAb SYN1351 is
pan specific, while each of the syntrophin peptide antibod-
ies is isoform-specific in immunoblotting and in immu-
noaffinity purification.
In addition to proteins of the size expected for full-
length syntrophins, smaller proteins were recognized by
the anti–b1- and anti–b2-syntrophin antibodies (Fig. 2).
These proteins were also recognized by mAb SYN1351,
thus confirming their identities as syntrophins. The tissue
distribution patterns for these smaller syntrophin-related
proteins are distinct from each other and from the corre-
sponding full-length isoforms (Fig. 3). Although it is possi-
ble that the smaller proteins are proteolytic fragments, a
more likely possibility is that they are generated by post-
translational modification or by alternative splicing of the
b1- and b2-syntrophin mRNAs. Northern blot analysis
identified multiple transcripts for b1- and b2-syntrophins,
while only a single transcript for a1-syntrophin was found
(1, 5, 6). Although the basis of these multiple transcripts is
unknown, it is certainly possible that they encode modified
forms of b1- and b2-syntrophins.
Differential Expression of Syntrophin Isoforms
To examine the relative amounts of the three syntrophin
isoforms expressed in different tissues, syntrophins were
partially purified from detergent-solubilized tissue extracts
using the pan-specific mAb SYN1351. Equal amounts of
total syntrophins from each tissue (as judged by immuno-
blotting with SYN1351) were subjected to immunoblotting
Figure 2. Isoform specificity
of syntrophin antibodies. An-
tibodies were characterized
by immunoblotting samples
enriched in individual syntro-
phin isoforms (as indicated
above lanes). a1-, b1-, and
b2-syntrophins were solubi-
lized from crude membrane
preparations from skeletal
muscle, liver, and kidney, re-
spectively, in 1% SDS to dis-
rupt potential multi-syntro-
phin complexes. After
addition of excess Triton,
syntrophins were immunoaf-
finity purified with the ap-
propriate antibody (Abs
SYN17, SYN37, and SYN28).
Blots were probed with mAb
SYN1351 or biotinylated
polyclonal antibodies as indi-
cated. Labeling with each
polyclonal antibody was
eliminated by preincubation
with the appropriate antigenic peptide (not shown). Positions of
two molecular mass markers (52 and 59 kD) are shown on the
right in the top panel.
Figure 3. Tissues express multiple syntrophin isoforms. Syntro-
phins were isolated from Triton X-100–solubilized tissue extracts
with the pan-specific syntrophin antibody SYN1351. Sample
loadings were adjusted to contain approximately equal amounts
of total syntrophin, as judged by immunoblotting with SYN1351
(pan anti-syn). Individual syntrophin isoforms were identified by
blotting with Abs SYN17 (anti–a1 syn), SYN37 (anti–b1 syn), or
SYN24 (anti–b2 syn). Positions of two molecular mass markers
(52 and 59 kD) are shown on the right in the top panel.Peters et al. Selective Pairing of Syntrophins with Dystrophin 85
with the isoform-specific antibodies (Fig. 3). The relative
tissue distribution of each syntrophin isoform is consistent
with previous Northern blot analysis (1, 5, 6). Thus, skele-
tal muscle contains the highest levels of a1-syntrophin,
while liver expresses the highest levels of b1-syntrophin,
and testis expresses predominantly b2-syntrophin. Almost
every tissue expresses two or three syntrophin isoforms,
but there did not appear to be any bias for particular pairs
of syntrophins to be expressed together.
Previously, we proposed that dystrophin and related
proteins might each be associated with a particular syntro-
phin isoform (1). This proposal was based largely on the
common expression patterns between dystrophin family
members and individual syntrophin isoforms. In vitro
binding studies have demonstrated, however, that all three
syntrophins are able to bind to a region in the COOH-ter-
minal domain of dystrophin encoded by exon 74, and to
the analogous regions in utrophin and dystrobrevin (6, 15),
with no intrinsic binding specificity. However, the associa-
tions that occur in vivo might be regulated by additional
factors. To examine this possibility, we have used a combi-
nation of immunofluorescence microscopy and biochemi-
cal analysis to determine which syntrophin isoforms are
associated with dystrophin, utrophin, and dystrobrevin
complexes.
Skeletal muscle was chosen for these studies for several
reasons. First, skeletal muscle expresses all three syntro-
phins, although a1-syntrophin is the predominant isoform
(see Fig. 3 and results in references 1, 5, 6). Since the dis-
tributions of dystrophin, utrophin, and dystrobrevin are
known in this tissue, a comparison of their localizations
with the syntrophin isoforms can be used to corroborate
the biochemical studies on isolated complexes. Further-
more, previous studies have shown that two syntrophins,
a1 and b2, have distinct distributions in muscle, an obser-
vation that supports the idea of differential association of
syntrophins and dystrophin family members (38). Finally,
Duchenne muscular dystrophy has its most profound ef-
fects on skeletal muscle. Since the absence of dystrophin
results in a loss of dystrophin-associated proteins, includ-
ing syntrophins, understanding syntrophin’s interactions in
this tissue may be especially important in deciphering the
molecular causes of this disease.
We performed immunofluorescence microscopy on sec-
Figure 4. Localization of syntrophin isoforms in skeletal muscle. Regions of mouse gastrocnemius muscle containing NMJs were identi-
fied by a-bungarotoxin (a-BgTx). Distributions of a1-, b1-, and b2-syntrophins were determined with Abs SYN17, SYN37, and SYN28,
respectively. In each case, the specificity of immunolabeling was confirmed in adjacent serial sections by preincubating antibodies with
the appropriate antigenic peptide. Bar, 50 mm.The Journal of Cell Biology, Volume 138, 1997 86
tions of adult mouse muscle with the syntrophin isoform-
specific antibodies. As reported previously (38, 55), la-
beling for a1-syntrophin was strong on sarcolemma with
particular enrichment at NMJs (Fig. 4). A similar labeling
pattern was identified for b1-syntrophin, although the stain-
ing intensity of individual fibers varied. Slow-twitch fibers
(type I) displayed little or no b1-syntrophin labeling, while
a subset of fast-twitch fibers (type II) showed intense la-
beling (Fig. 5 A). Among fast fibers, the most glycolytic
ones (type IIB) showed stronger labeling than oxidative fi-
bers (type IIA and D) (Fig. 5 B). Although this was the
typical staining pattern, exceptions could be found. For ex-
ample, in predominantly fast muscles, staining for b1-syn-
trophin in slow fibers was weak but clearly detectable (not
shown). In contrast, differential staining of fiber types was
not seen for a1-syntrophin (Fig. 5 A) or dystrophin (22).
We have previously shown that b2-syntrophin is concen-
trated at NMJs (38). This labeling pattern was established
on rat skeletal muscle with Ab SYN24, which reacts only
weakly with mouse b2-syntrophin. We have now prepared
an additional antibody, SYN28, which gives much stronger
labeling of b2-syntrophin at the neuromuscular junction in
mouse and rat skeletal muscle. In both rat and mouse,
faint but specific labeling for b2-syntrophin was occasion-
ally detected on the sarcolemma with Ab SYN28 (Fig. 4).
Thus, although it is likely that small amounts of this iso-
form are also present on the sarcolemma, these results are
in general agreement with our original finding that b2-syn-
trophin is concentrated at the NMJ. Thus, each of the
three syntrophins exhibits a differential distribution in
skeletal muscle, either within a single muscle fiber or
across muscle fiber types.
Multiple Syntrophin Isoforms in Dystrophin and 
Utrophin Complexes
Previous biochemical studies showed that purified dystro-
phin complexes contain a triplet of syntrophin bands (55).
Figure 5. Fiber-type specific-
ity of b1-syntrophin. (A)
Syntrophins were examined
in sections of mouse hind
limb muscle containing the
mixed slow/fast-twitch plan-
taris (left of arrows) with the
adjacent fast-twitch gastroc-
nemius (right of arrows). La-
beling for a1- and b1-syntro-
phins (SYN17 and SYN37) is
compared to that of fast fiber
(type II) MHC staining
(mAb NCL-MHCf). Note
that  b1-syntrophin labeling is
highly restricted to a subset
of type II myofibers, while
a1-syntrophin labeling shows
uniform fiber-type staining.
(B) b1-syntrophin labeling
was examined in subtypes of
fast fibers identified by mAb
BF-F3 specific for type IIB
MHC (IIB) and mAb A4.74
specific for IIA, and to a
lesser extent type IID MHC
(IIA, D). b1 and IIA, D show
a single cryosection double
labeled as indicated, while
IIB shows an adjacent serial
section. Note the correspon-
dence between strong label-
ing for b1-syntrophin (b1)
and that of type IIB myosin
(IIB). Bars: (A) 50 mm; (B)
80 mm.Peters et al. Selective Pairing of Syntrophins with Dystrophin 87
However, the isoform identity of these syntrophin bands
was not determined. Likewise, the syntrophin isoforms
associated with utrophin in skeletal muscle have not been
established. To determine which syntrophin isoforms are
present in dystrophin and utrophin complexes, we par-
tially purified dystrophin and utrophin from skeletal
muscle extracts using immunoaffinity purification. When
isolated in this way, dystrophin preparations contain no
detectable utrophin, and utrophin preparations are free of
detectable dystrophin (Fig. 6 A). Given the relative pau-
city of NMJ membrane (the site of highest concentration
of utrophin) in skeletal muscle fibers, it is likely that much
of the utrophin complex originated from nerve and blood
vessels. In addition to the full-length utrophin (predicted
to be 395 kD), a smaller utrophin-immunoreactive protein
was identified. This z140-kD protein appears to be larger
than G-utrophin and thus may either result from proteoly-
sis of full-length utrophin or represent a previously unde-
scribed utrophin homologue of Dp140. Aliquots of dystro-
phin and utrophin complexes containing approximately
equal amounts of total syntrophin were analyzed by im-
munoblotting, thereby allowing comparison of the relative
amounts of individual syntrophin isoforms. As shown in
Fig. 6 A, dystrophin complexes were highly enriched in a1-
and b1-syntrophins, while utrophin complexes contained
mostly b1- and b2-syntrophins.
To corroborate these results, syntrophin isoform com-
plexes were isolated by immunopurification. Samples con-
taining approximately equal amounts of total syntrophin
were then tested for relative levels of dystrophin and utro-
phin. As shown in Fig. 6 B, a1-syntrophin preparations
were particularly enriched in dystrophin, while b1- and b2-
syntrophin preparations contained smaller amounts of
dystrophin. The same blot was stripped and reprobed for
utrophin. Highest levels of utrophin were found in the b2-
syntrophin preparations, while lower levels were detected
in the b1-syntrophin preparations (Fig. 6 B). Only with
much longer exposures was utrophin detected in a1-syn-
trophin complexes. Together, these results indicate that, in
skeletal muscle, dystrophin associates preferentially with
a1- and b1-syntrophin. In contrast, utrophin complexes
contain predominantly b1- and b2-syntrophin.
Syntrophin Distribution in mdx Skeletal Muscle
Previous studies with the pan-specific syntrophin mAb
SYN1351 showed that the loss of dystrophin from the sar-
colemma causes a dramatic decrease of syntrophin stain-
ing (11). This decrease occurred despite the fact that total
syntrophin, as measured by immunoblot analysis, was es-
sentially unchanged in mdx muscle. To determine which
isoforms are affected, we compared syntrophin isoform
staining in normal and mdx gastrocnemius muscle. In wild-
type mice, fibers of the gastrocnemius muscle, which are
predominantly fast fiber type, have high levels of a1- and
b1-syntrophins on the sarcolemma. However, in mdx mus-
cle, the absence of dystrophin results in a dramatic reduc-
tion of both a1- and b1-syntrophin sarcolemmal staining
(compare Fig. 7, A and B, to Fig. 4). This result provides
further support for the association of a1- and b1-syntro-
phins with dystrophin.
At some sites in mdx muscle, intense syntrophin staining
was retained, and in each case, its distribution paralleled
that of utrophin. As previously shown (38, 55), labeling for
a1-syntrophin in mdx muscle was particularly strong at the
NMJ, a site of high utrophin concentration (Fig. 7 A). Stain-
ing for b1- and b2-syntrophin was also retained at the
NMJ (Fig. 7 A). Utrophin labeling frequently extended be-
yond its normal highly restricted distribution on the post-
synaptic membrane, spilling over onto the perisynaptic sar-
colemma and diminishing in intensity with distance from
the NMJ (Fig. 7 A). a1- and b1-syntrophins, and to a lesser
extent b2-syntrophin, were also found perisynaptically in
mdx muscle (Fig. 7 A).
Figure 6. Dystrophin and utrophin complexes contain distinct pairs
of syntrophin isoforms. (A) Dystrophin and utrophin complexes
were immunoaffinity purified from Triton-solubilized extracts of
mouse skeletal muscle with antibodies DYS3669 and UTR3165,
respectively. Sample loadings were adjusted to contain approxi-
mately equal amounts of syntrophin, as judged by immunoblot-
ting (pan-Syn, mAb SYN1351). Duplicate blots were probed with
mAbs Mandys-8 (Dys), and DRP-1 (Utr) or biotinylated poly-
clonal antibodies SYN17 (a1-syn), SYN37 (b1-syn), and SYN28
(b2-syn). (B) Syntrophins were immunoaffinity purified from
skeletal muscle extracts with Abs SYN17, SYN37, and SYN28.
Sample loadings were adjusted to contain similar amounts of to-
tal syntrophin, as judged by immunoblotting (pan-Syn, mAb
SYN1351). A duplicate blot was probed with mAb Mandys-8
(Dys), stripped, and reprobed with mAb DRP-1 (Utr). Positions
of molecular mass markers (in kD) are shown in some panels.
These results were replicated twice, and representative blots from a
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In nonsynaptic regions, utrophin labeling was frequently
seen on small caliber myofibers with centrally located nuclei,
the hallmark of regenerated fibers (Fig. 7 B). In adjacent
serial sections, staining for a1-syntrophin and especially
b1-syntrophin mirrored that of utrophin. b2-syntrophin
was not detectable under standard labeling conditions.
These fibers are not revertants since antidystrophin label-
ing was negative (Fig. 7 B). Thus, although syntrophin im-
munoreactivity is dramatically reduced on the sarcolemma
of mdx skeletal muscle, staining for at least two isoforms is
retained in regions that express utrophin. When consid-
ered with the results of immunoaffinity purification, these
data suggest that utrophin is capable of associating with
each syntrophin isoform.
Two Syntrophin-binding Sites in the
Dystrophin Complex
Results from other laboratories suggest that the syntro-
phin content in purified dystrophin complexes is approxi-
mately twice that of other dystrophin-associated proteins
(16, 56). While only a single syntrophin-binding region has
been clearly identified on dystrophin, a second syntrophin-
binding protein, dystrobrevin, is known to be associated
with the dystrophin complex in skeletal muscle (50, 51).
Originally identified as a Torpedo phosphoprotein of 87
kD (51), dystrobrevin is homologous to the COOH-termi-
nal region of dystrophin and contains a syntrophin-binding
site (4, 15). This site is followed by two tandem heptad re-
peats of leucines predicted to form coiled-coils (7). Ozawa
and colleagues have shown that dystrophin binds in vitro
to a protein called A0, and they have mapped its binding
site to the first heptad repeat of dystrophin (50). Subse-
quently, A0 was shown to be equivalent to dystrobrevin
(58). A weaker binding site was found in the region of dys-
trophin that contains the second heptad repeat (50). Thus,
we propose a model in which dystrophin and dystrobrevin
associate via coiled-coil interactions (7) and could thus re-
cruit two syntrophins to the dystrophin complex.
In complexes that contain two syntrophin-binding pro-
teins (dystrophin and dystrobrevin), it is difficult to deter-
mine the type of syntrophin associated with either protein
independently. In this regard, the D71–74 transgenic mdx
mouse is particularly useful since it expresses a dystrophin
transgene in skeletal muscle that lacks exons 71–74, which
includes the syntrophin-binding site (for review see refer-
ence 18). In mdx muscle, D71–74 dystrophin produced by
the transgene is targeted to the sarcolemma, such that nor-
mal levels of membrane-bound dystrophin-associated pro-
teins are restored (39, 40). Surprisingly, the D71–74 dystro-
phin transgene restores syntrophin immunoreactivity to
the sarcolemma, despite lacking the syntrophin-binding
Figure 7. Localization of
syntrophins in mdx mouse
skeletal muscle. (A) The dis-
tribution of syntrophin iso-
forms was examined in re-
gions containing NMJs
(identified with a-bungaro-
toxin; Tx). Labeling in the
perisynaptic regions with an-
tibodies SYN17 (a1), SYN37
(b1), SYN28 (b2), and
UTR3165 (Utr) was charac-
terized. (B) In 8-wk-old mdx
mice, regenerating fibers
with central nuclei were
identified by haematoxylin-
eosin (H&E) staining. Serial
sections were labeled with
antibodies UTR3165 (Utr),
DYS3669 (Dys), SYN17
(a1), SYN37 (b1), and
SYN28 (b2). Bars: (A; a1,
b1, and Utr) 50 mm; (A; B2)
30 mm; (B) 50 mm.Peters et al. Selective Pairing of Syntrophins with Dystrophin 89
site (39, 40). Since the D71–74 dystrophin transgene prod-
uct retains most of the coiled-coil region encoded by exon
75, it might still associate with dystrobrevin, which could in
turn bind syntrophin and target it to the membrane. In-
deed, we find dystrobrevin localized on the sarcolemma
along with both a1- and b1-syntrophins (Fig. 8 B). Thus,
a1- and b1-syntrophins may be restored to the membrane
in these transgenic mice via association with dystrobrevin
bound to dystrophin.
As an additional test of association of a1- and b1-syn-
trophins with dystrobrevin, we immunoaffinity purified
dystrobrevin from D71–74 transgenic mdx mouse skeletal
muscle. Using an antibody (DB308) directed against a cen-
tral region of dystrobrevin, we purified complexes and
Figure 8. Dystrobrevin associ-
ates with a1- and b1-syntro-
phins in D71–74/mdx skeletal
muscle. (A) Schematic com-
paring the structure of the cys-
teine-rich COOH-terminal re-
gion of normal dystrophin, of
the dystrophin transgene lack-
ing exons 71–74, and the corre-
sponding structure of dystro-
brevin. The locations of the
sequences used for prepara-
tion of dystrobrevin antipep-
tide antibodies DB308 and
DB433 are indicated by bars.
H1, H2, and WW, position of
helix 1 and helix 2 and the WW
domain, respectively. (B) Im-
munofluorescence labeling for
a1-syntrophin (a1, Ab
SYN17),  b1-syntrophin (b1,
Ab SYN37), and dystrobrevin
labeling (Db, mAb 13H1), with
the corresponding labeling with
a-bungarotoxin (Tx) shown to
the right of each image. The la-
beling for b2-syntrophin (b2,
Ab SYN28) and a-bungaro-
toxin (Tx) was reduced in size
and intensity compared to con-
trol mice. (C) Dystrobrevin
complexes were immunoaffin-
ity purified from Triton ex-
tracts of D71–74/mdx skeletal
muscle with antipeptide dys-
trobrevin antibodies that recog-
nize either a central region (Ab
DB308, left lane) or the linker
between the two coiled-coils
(Ab DB433, right lane). Sample
loadings were adjusted for ap-
proximately equal amounts of
dystrobrevin immunoreactivity
in each lane (Db, mAb 13H1).
Complexes purified with Ab
DB433 contained dramatically
lower amounts of dystrophin,
as expected if this antibody in-
hibits a coiled-coil interaction
between dystrophin and dys-
trobrevin; see text (Dys,
Mandys-8). The total amount
of syntrophin (pan-Syn, mAb
SYN1351) purified with dys-
trobrevins was approximately
the same with either Db antibody. Both a1-syntrophin (a1-syn, Ab SYN17) and b1-syntrophin (b1-syn, Ab SYN37) copurified with dys-
trobrevin, independent of the presence of dystrophin. Utrophin and b2-syntrophin were detectable only with much longer exposure
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found that both a1- and b1-syntrophins and D71–74 dys-
trophin copurified with dystrobrevin (Fig. 8 C, lanes DB308).
Complexes isolated with a second dystrobrevin antibody,
Ab DB433 made against the short linker region between
dystrobrevin’s coiled-coils (see Fig. 8 A), also contained
a1- and b1-syntrophins. These results suggest that dystro-
brevin can associate with either syntrophin isoform in vivo.
We did note one important difference in the dystrobre-
vin complexes isolated with Abs DB308 and DB433. The
dystrophin content in Ab DB433 preparations was dra-
matically reduced in comparison with the amounts ob-
tained when Ab DB308 was used (Fig. 8 C, lanes DB433).
It appears that Ab DB433, which recognizes the linker se-
quence between the coiled-coils of dystrobrevin, disrupts
the interaction between dystrophin and dystrobrevin. Al-
ternatively, it is possible that the epitope for Ab DB433 is
more accessible in dystrobrevins that are not bound to
dystrophin. Both of these possibilities are consistent with
the idea that interaction between dystrobrevin and dystro-
phin is mediated by their coiled-coil regions.
Discussion
The syntrophins are a multigene family of modular
adapter proteins thought to recruit signaling proteins to
the membrane via association with dystrophin and other
members of the dystrophin family. The existence of three
isoforms derived from distinct genes makes the syntro-
phins unique among dystrophin-associated proteins. In
skeletal muscle, we find that the syntrophins have distinct
but overlapping distributions. These differential localiza-
tions imply that each syntrophin has a unique function,
probably derived in part from association with either dys-
trophin or utrophin, in combination with dystrobrevin.
Our results suggest that pairs of syntrophin isoforms as-
sociate with dystrophin and utrophin complexes. Previous
stoichiometric analyses of purified dystrophin complexes
is in good agreement with two syntrophins per complex
(16, 56). Several features of the dystrophin complex could
account for the presence of two syntrophins. In addition to
the known syntrophin-binding site in dystrophin encoded
by the first half of exon 74 (4, 50), a second syntrophin-
binding site has been proposed. A peptide corresponding
to the latter half of 74 and exon 75 of dystrophin binds an
z60-kD DAP (50). Although this protein was thought to
be b1-syntrophin, it may instead be the 60-kD form of dys-
trobrevin. Indeed, the peptide also bound a larger protein
(A0) (50), which has since been identified as full-length
dystrobrevin (58). Thus, the putative second syntrophin-
binding site, which encompasses the first coiled-coil of dys-
trophin, may instead be a site of interaction between dys-
trophin and dystrobrevin. A second possibility is that two
syntrophins in a dystrophin complex could result from syn-
trophin dimerization. Syntrophins have been shown to
bind an z60-kD DAP, leading to the suggestion that syn-
trophins form dimers (55). However, this binding may also
represent syntrophin association with the z60-kD dystro-
brevin. In fact, syntrophin also bound a larger protein of
the approximate molecular weight of full-length dystro-
brevin (55). Finally, multiple syntrophins may also be re-
cruited to dystrophin complexes by association with other
DAPs (31).
The model we favor incorporates a previous proposal (7)
that dystrophin and dystrobrevin interact via their coiled-
coils. Considerable evidence, including new results that we
present here, supports an association of dystrophin with dys-
trobrevin. Dystrophin and dystrobrevin colocalize in skeletal
muscle (8, 12), copurify biochemically (51), and associate
directly in vitro via the coiled-coil region of dystrophin
(50). We now find that dystrobrevin complexes isolated
with an antibody to the coiled-coil region of dystrobrevin
contain only small amounts of dystrophin when compared
to complexes isolated with an antibody directed to another
site. Thus, antibody binding to the coiled-coil region is in-
compatible with dystrophin–dystrobrevin association. Fi-
nally, purified dystrophin complexes can be partially disso-
ciated into three groups, a dystroglycan subcomplex, a
sarcoglycan subcomplex, and a dystrophin–dystrobrevin–
syntrophin subcomplex by treatment with n-octyl b-d-glu-
coside (57). Detailed characterization of this association
will be needed to determine the precise stoichiometry and
binding orientation of the coiled-coil interaction. Despite
this reservation, the evidence for an interaction between
dystrophin and dystrobrevin is quite strong and leads us to
suggest a new model for the dystrophin COOH-terminal
region in which dystrophin and dystrobrevin combine to
recruit two syntrophins per complex (Fig. 9 A).
In skeletal muscle, which expresses all three syntrophin
isoforms, particular pairs of syntrophins preferentially as-
sociate with dystrophin or utrophin complexes. These
preferential associations are not likely to result from in-
trinsic selectivity of either dystrophin or utrophin for par-
ticular syntrophins. Previous studies have shown that dys-
trophin, utrophin, and dystrobrevin are each able to bind
any of the three syntrophin isoforms in vitro (5, 6). From
our studies of native complexes from control, mdx, and
mdx transgenic mice, we conclude that these associations
are selective but not absolutely exclusive. Nevertheless,
the pairings of syntrophin isoforms with dystrophin family
members appear to be more highly regulated than sug-
gested by in vitro studies. Potential mechanisms that could
account for this selectivity include cell-specific expression of
particular syntrophin isoforms and posttranslational modi-
fications, such as phosphorylation, that alter the binding
affinity of syntrophins for dystrophin and related proteins.
Since the pairing of syntrophin isoforms is thus unlikely
to be determined by intrinsic selectivity for dystrophin
family members, several possible pairings within an individ-
ual dystrophin–dystrobrevin complex can be envisioned.
For example, the observed pairing of a1- and b1-syntro-
phins with dystrophin could represent either a1/b1 het-
erodimers or similar amounts of a1/a1 and b1/b1 homo-
dimers with dystrophin. Indeed, these two possibilities are
not mutually exclusive and may both occur in a single
membrane region or may be differentially regulated at par-
ticular membrane regions. Distinguishing between these
two possibilities in native complexes may prove techni-
cally difficult. Perhaps identification of the mechanisms
that determine the syntrophin pairs may help to address
these possibilities.
Syntrophins in Duchenne Muscular Dystrophy
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other myopathies has not received much attention, despite
the fact that sarcolemmal expression of syntrophins, like
that of the other proteins of the dystrophin complex, is
dramatically reduced in Duchenne muscular dystrophy
(DMD). Defects in other proteins of the dystrophin com-
plex are the primary causes of other muscular dystrophies
in which dystrophin is normal. For example, mutations in
the genes encoding the sarcoglycans have been implicated
in severe childhood autosomal recessive muscular dystro-
phy and in several forms of limb-girdle muscular dystro-
phy (for review see reference 37). Although no myopa-
thies or other diseases have been linked to primary defects
in syntrophins, our finding that b1-syntrophin is enriched
in fast-twitch type IIB muscle fibers raises new issues with
regard to the importance of syntrophins in DMD. Nor-
mally, dystrophin is expressed in all myofiber types (23),
yet DMD preferentially affects human fast type IIB fibers
(52). Although the mechanisms underlying this selective
pathology remain to be determined, an intriguing possibil-
ity is that among the syntrophins, the function of b1-syn-
trophin is particularly important in maintaining sarcolem-
mal integrity.
Identifying other proteins associated with b1-syntrophin
may be particularly relevant to understanding the molecu-
lar origin of the DMD myopathy. One possibility is that
b1-syntrophin mediates the targeting of the neuronal form
of nitric oxide synthase (nNOS) to the membrane. Like
b1-syntrophin, nNOS is expressed preferentially in fast-
twitch myofibers and is the only other protein known to
correlate so closely with the fiber-type specific onset of
DMD (26, 52). In normal muscle, nNOS is found on the
sarcolemma in association with the dystrophin complex
(9). This association is mediated, at least in part, by PDZ–
PDZ heterodimerization between nNOS and syntrophin
(10). Thus far, this nNOS interaction has been studied
only in vitro with a1-syntrophin. It is possible that in vivo
b1-syntrophin alone or paired with a1-syntrophin may be
essential for targeting of nNOS to the sarcolemma, and
could thus explain the fiber-type differences seen for this
enzyme.
The physiological role of nNOS in normal skeletal mus-
cle remains unknown, although some results suggest that it
promotes muscle relaxation through a cGMP signaling
pathway (26). The mechanism by which nNOS is activated
in skeletal muscle is also poorly understood, although it is
known that activation requires calcium/calmodulin and
nNOS homodimerization (25). Neither the source of acti-
vating calcium nor the requirements for dimerization has
been determined. Syntrophin association may play a role
in both aspects of nNOS regulation. For example, close
pairing of two syntrophins (discussed below) may facilitate
nNOS dimerization, while syntrophin-mediated membrane
localization may target nNOS to an appropriate Ca21
source. Furthermore, loss of the syntrophin–nNOS com-
plex from the membrane in dystrophic muscle may disrupt
the nNOS-mediated relaxation pathway in favor of inap-
known. Utrophin complexes contain b1- and b2-syntrophins. The
binding partners for both syntrophins may be of particular rele-
vance to NMJ function. DGC, dystroglycan complex; SGC, sar-
coglycan complex.
Figure 9. (A) Hypothetical model of the dystrophin complex
containing two syntrophin-binding proteins. Syntrophins bind the
exon 74–encoded region of dystrophin and the homologous re-
gion of dystrobrevin (6, 15). In both proteins, the syntrophin-
binding site is followed by two heptad repeats of leucines (H1
and H2), separated by a short linker region (7). (B) Hypothetical
examples of syntrophin isoform combinations as adapters linking
membrane proteins or effector enzymes to dystrophin and utro-
phin. In fast-twitch myofibers, a1- and/or b1-syntrophin bind
nNOS (10). In slow-twitch myofibers, a1-syntrophin is the pre-
dominant isoform present on the sarcolemma. Since slow-twitch
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propriate cytoplasmic nNOS activation. This combination
of loss of a potentially protective activity and acquisition
of a potentially cytotoxic function may be central to DMD
pathogenesis.
Syntrophins at the Neuromuscular Synapse
All three syntrophins are concentrated at the NMJ, but
only b2-syntrophin is highly restricted to the synapse. a1-
and b1-syntrophins are found on the entire sarcolemma
with particularly high concentrations at synapses, a distri-
bution similar to dystrophin. In contrast, the distribution
of b2-syntrophin more closely resembles that of utrophin.
Using immunoaffinity purification from whole skeletal
muscle, we find that dystrophin preparations are enriched
in a1- and b1-syntrophins, while utrophin complexes con-
tain b1- and b2-syntrophin. Thus, while it is tempting to
speculate that these preferential syntrophin–dystrophin/
utrophin pairings hold within the postsynaptic apparatus,
two considerations make this conclusion premature. First,
we find that all three syntrophins remain concentrated at
the NMJ in mdx mice, possibly in association with utro-
phin. Second, the utrophin complexes isolated from skele-
tal muscle by biochemical means are not derived exclu-
sively from the postsynaptic membrane, but come in large
part from nonmuscle cells. Thus, it remains to be seen
which syntrophin or combination of syntrophins colocalize
with utrophin at the AChR-rich crests of the postsynaptic
folds, or with dystrophin in the troughs, the site of high so-
dium channel density. Future studies will address this issue
and the identification of synapse-specific binding partners
for b2-syntrophin since it is unique among all the DAPs in
its restriction to the postsynaptic apparatus.
Paired Syntrophins: Implications for Function
The discovery of two syntrophin isoforms in dystrophin/
utrophin complexes has clear implications for the mecha-
nism of syntrophin function within membrane specializa-
tions. Specifically, the pairing of two PDZ-containing
proteins in a submembrane complex resembles the mem-
brane-associated guanylate kinase (MAGUK) complex. Like
the syntrophins, the MAGUKs are a multigene family of
PDZ-containing proteins that form submembranous pro-
tein scaffolds. The best characterized MAGUKs are the
neuronal forms: PSD-95, Chapsyn-110, SAP97, and SAP102,
which when expressed in COS cells combine to form ho-
motypic and heterotypic multimers (24). MAGUKs have
recently been shown to cluster membrane proteins such as
K1 channels and NMDA-type glutamate receptors (for
review see reference 48). The PDZ domains of certain
MAGUKs mediate binding to the extreme COOH termi-
nus of the cytoplasmic tail of membrane proteins (14, 49).
Because this binding is dependent on the sequence of the
COOH-terminal tail of the membrane protein, different
MAGUK isoforms appear to bind different sets of mem-
brane proteins. Thus, the combination of MAGUK iso-
forms at a particular membrane site may determine the
composition of membrane proteins clustered there.
In contrast to the MAGUKs, which have three PDZ do-
mains, syntrophins have only a single PDZ motif. This
would appear to limit the ability of syntrophins to act as
adapters in membrane organization by binding simulta-
neously multiple types of membrane proteins (such as ion
channels) or a single membrane protein and an effector
enzyme (such as nNOS). However, an attractive feature of
the model in which two syntrophins are present in a single
dystrophin complex is that each simultaneously could bind
different proteins. Furthermore, a single complex might
bind different combinations of proteins, depending on the
specificity of the syntrophin PDZ domains. Thus, by regu-
lating the syntrophin isoforms associated with dystrophin
and dystrobrevin, or utrophin and dystrobrevin, the asso-
ciated membrane or signaling protein might be different.
The models shown in Fig. 9 show hypothetical combina-
tions that might confer distinct functions on utrophin and
dystrophin complexes, depending on the binding partners
for the syntrophin PDZ domains.
Further studies will be required to determine if syntro-
phins play a role similar to that of the MAGUKs in mem-
brane organization. Identifying the syntrophin PDZ do-
main binding partners and understanding the mechanisms
that regulate the combinations of syntrophin isoforms in
dystrophin complexes will be important for understanding
the role of syntrophins in muscular dystrophy and in syn-
apse formation.
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